profit from every $100 of sales.
$0$100
National Research
$26.86+0.04% today
+79.9% in 1 year
1-year low $12.031-year high $27.07
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $49.14 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What National Research sold, what it kept, and what it did with the cash.
Sales went from $152 million in 2022 to $137 million in 2025, with $11.6 million of profit last year.
SalesProfit
National Research handed back more cash to shareholders than it generated last year.
Buybacks $20M$11M
Free cash flow 2025$16M
Bought back its own shares$20M
Paid as dividends$11M
Cash vs. debt$4M vs. $79M
National Research vs. similar companies
National Research grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| National Research | 49.1× · Expensive | ||
 GE HealthCare Technologies | 17.9× · Fair price | ||
 Tempus AI | No profit yet | ||
 BrightSpring Health Services | 75.8× · Very expensive | ||
 HealthEquity | 39.6× · Expensive |
AI analysis
An AI analyst reads National Research's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 152 | 149 | 143 | 137 | |
| 95 | 93 | 86 | 85 | |
| 47 | 40 | 35 | 23 | |
| 49 | 47 | 41 | 30 | |
| 32 | 31 | 25 | 12 | |
| 1.27 | 1.25 | 1.04 | 0.50 | |
| 62.4% | 62.3% | 60.2% | 61.9% | |
| 30.7% | 27.0% | 24.6% | 16.4% | |
| 21.0% | 20.8% | 17.3% | 8.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 130 | 122 | 133 | 135 |
| Cash | 25 | 7 | 4 | 4 |
| Total debt | 22 | 37 | 63 | 79 |
| Total liabilities | 58 | 73 | 101 | 121 |
| 72 | 49 | 31 | 14 | |
| 25 | 25 | 24 | 22 | |
| 36.9% | 37.7% | 29.7% | 19.2% | |
| 44.1% | 63.3% | 79.2% | 82.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 36 | 38 | 35 | 26 | |
| 10 | 16 | 15 | 11 | |
| 26 | 22 | 19 | 16 | |
| Dividends paid | 21 | 36 | 11 | 11 |
| 28 | 19 | 31 | 20 | |
| 1 | 1 | 0 | 3 |
Valuation
- 49.1×
- 30.5×
- –
- 31.5×
- 4.1×
- 36.2×
- 21.3×
- 2.8%
- 2.0%
- 2.9%
Profitability
- 61.9%
- 16.4%
- 8.4%
- 20.1%
- 12.2%
- 28.0%
- 57.2%
- 6.7%
- 20.4%
- –
Growth
- −3.2%
- −26.7%
- −17.9%
- +19.9%
- −3.1%
Financial health
- 2.7×
- 5.78
- 58.0%
- 3.8×
- 0.52
- 0.52
- 1.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 20%of 958
Top 30%of 889
Bottom 22%of 601
Bottom 12%of 890
Top 37%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | 0.21 | – | – |
| Feb 3, 2026 | 0.16 | – | – |
| Oct 27, 2025 | 0.23 | – | – |
| Jul 28, 2025 | 0.28 | – | – |
| Apr 28, 2025 | 0.25 | – | – |
| Feb 11, 2025 | 0.36 | – | – |
| Oct 25, 2024 | 0.24 | – | – |
| Aug 6, 2024 | 0.26 | – | – |
2.9%of the share price, paid each year
On $1,000 invested$29a year at today's yield, before tax
+19.9%2020 to 2025
Raised1 yearin a row, in our data
Paid per share, each year
$0.62 in 2015 → $0.52 in 2025
How safe it looks
94.6% of its profit
Room to growStretchedMore than it earns: 69.7%
News
National Energy Services Reunited declares $0.10 dividendSeeking Alpha · Nov 10, 20263 US Defense Stocks Worth Watching As Nvidia Questions Hit National SecurityYahoo Finance · Nov 9, 2026NRC expects further sequential margin improvement in Q4 as rounding phase targets Q3 2027 go-liveSeeking Alpha · Oct 27, 2026Auburn National GAAP EPS of $0.72, revenue of $9.1MSeeking Alpha · Oct 27, 2026NuScale Power Trades Below $6 With the Only NRC-Certified Small Modular Reactor Design. Here's Why That Still Isn't Enough.Yahoo Finance · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
18No pass
Philip Fisher
45No pass
Peter Lynch
10No pass
Joel Greenblatt
13No pass
Charlie Munger
52No pass
Terry Smith
52No pass
Questions about National Research
Is National Research a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the National Research AI analysis
What does National Research do?
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. It is in Medical - Healthcare Information Services.
Does National Research pay a dividend?
Yes. At today's price the dividend is 2.9% a year, about 95% of its yearly profit. In 2025 it paid out $11.0 million in dividends.
Is National Research stock halal?
Yes. National Research passes our halal screen: its business is permitted and its debt is 14% of its market value, under the 30% limit. How we check
How has National Research stock done over the past year?
Up 79.9% over the past twelve months, to $26.86. It traded between $12.03 and $27.07, close to its high.
Who are National Research's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, Tempus AI, BrightSpring Health Services and HealthEquity. The peers table on this page compares their profit, growth and price with National Research's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.